Good day, ladies and gentlemen, and welcome to the NeoGenomics 4th Quarter and Fiscal Year 2019 Earnings Release Conference Call. All lines have been placed on a listen only mode and the floor will be open for your questions and comments following the presentation. At this time, it is my pleasure to turn the floor over to your host for today, CEO, Mr. Doug Van Aort. Sir, the floor is yours.
Thank you, Jess. Good morning, everyone. I'd like to welcome everyone to NeoGenomics' 4th quarter 2019 conference call. Our team is here together in San Antonio at our annual national sales meeting. And joining me for this call is Catherine McKenzie, our Chief Financial Officer Rob Shovlin, President of our Clinical Division George Cardoza, President of our Pharma Services Division Bill Bonello, President of our Informatics Division and Director of Investor Relations Doctor.
Larry Weiss, our Chief Medical Officer and Doug Brown, our Chief Strategy and Corporate Development Officer. Before we begin our prepared remarks, Bill Bonello will read the standard language about forward looking statements.
This conference call may contain forward looking statements, which represent our current expectations and beliefs about our operations, performance, financial condition and growth opportunities. Any statements made on this call that are not statements of historical fact are forward looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond our control. Should 1 or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, actual outcomes and results could differ materially from those indicated in the forward looking statements. Any forward looking statement speaks only as of today, and we undertake no obligation to update any such statements to reflect events or circumstances after today.
Before turning the call back to Doug, I want to let everyone know that we'll be making a copy of our prepared remarks for this morning's call available in the Investor Relations section of our website shortly after the call is completed. We also want to let everyone know that we're going to limit the number of questions to 2 per person in order to give more people a chance to ask questions within the 1 hour that's been allotted for this call.
Thank you, Bill. For today's call, I'll briefly review some quarter 4 highlights. Catherine McKenzie will then provide a more detailed review of the financial results, and I'll then share with you several initiatives and investments that we're making to drive both near term and long term growth. We'll then have time for questions and answers. Before I discuss the results, I would like to discuss a couple of important additions to our leadership team.
First, we are delighted to introduce Catherine McKenzie as our Chief Financial Officer. Many of you already know I would also like to introduce Doug Brown, who joins us as Chief Strategy and Corporate Development Officer. Doug joins us from SVP Leerink where he was a Senior Managing Director. Doug brings years of experience in the oncology diagnostics sector and has been a longtime advisor and trusted friend of our company. We couldn't be more pleased to have Catherine and Doug join our leadership team.
I also want to recognize and congratulate Bill Bonello, who in addition to continuing to lead and direct our Investor Relations process is now the President of our Informatics division, a newly created and exciting strategic initiative for our company. Now let's turn to 2019 full year and quarter 4 highlights. 2019 was an outstanding year for NeoGenomics. We grew revenue by nearly 50%, including greater than 20% organic growth and increased gross margin by more than 200 basis points year over year to 48.1%. More importantly, we significantly strengthened our competitive position as a leading global oncology diagnostic company.
4th quarter revenue increased 40% year over year to $107,000,000 As a reminder, Genoptix was included in part of last year's Q4. Importantly, organic revenue growth once again exceeded 20%. Both divisions had very strong performance. In the Q4, clinical division test volumes increased 27% year over year with combined company organic volume growth of approximately 14%. We are pleased that even during an integration year, organic growth rates accelerated each quarter since we acquired Genoptix in December 2018.
We continue to drive growth across all testing modalities with particular strength in next generation sequencing and molecular testing, which once again grew by approximately 50%. We believe that our test volume growth rates reflect a steady increase in market share. The growth also results from very high customer retention rates and are reflective of our continued high measures of customer satisfaction. Clinical division revenue per test increased 11% to $3.70 per test, marking the 6th straight quarter in which revenue per test has increased on a year over year basis. That increase primarily reflects the addition of Genoptix and a favorable change in the mix of test volume as next generation sequencing and flow cytometry volume are growing at higher relative rates.
Pharma Services revenue increased 27% year over year to more than $13,000,000 New contracts signed in the quarter were a record $33,000,000 and the backlog of signed contracts increased 32% year over year to more than $130,000,000 With the recent acquisition of the oncology division assets of human longevity, our backlog is now approximately $145,000,000 In pharma services, we continue to benefit from our domain expertise, global expansion, investments in flow cytometry, global alliance with PPD and positioning for companion diagnostics. Over the course of 2019, we assisted numerous pharmaceutical companies in securing FDA approvals for their therapies. The pharma business is stronger than it has ever been and is well positioned to capitalize on a robust environment for oncology therapy development. In terms of profitability, we are in a holding pattern as we work towards completion of the Genoptix integration. While gross margin was up more than 200 basis points for the year, In the Q4, gross margin was down 180 basis points year over year to 46.7 percent, primarily because we are in the final throes of integration related activities.
Expect to see a more substantial improvement in margins in the second half of twenty twenty as we realize Genoptix related cost synergies and are able to focus on the type of cost and productivity improvements that have been a hallmark of our operations for years. In summary, we are pleased with our full year and the quarter 4 results and feel very good about our outlook for the future. I will now turn the call over to Catherine McKenzie, our Chief Financial Officer, to discuss some of the details of quarter 4 financial results.
Thank you, Doug. Doug already commented on the key points of revenue and profitability, so I will focus my commentary on some of the other financial metrics in the quarter. On a full year basis, gross margin for our Clinical Services division increased 160 basis points to 48.6 percent, primarily driven by improvements in revenue per test. For the 4th quarter, clinical services gross margin was down 120 basis points sequentially, primarily due to increased hiring to accommodate both integration and anticipated growth. As a reminder, we staffed up significantly in the 3rd 4th quarters in both the Clinical Services and Pharma Services divisions to support existing and anticipated growth and complete the transition of Genoptix clients to a common laboratory system and process.
In 2019, our average cost of goods sold per clinical test, also known as our cost per test, increased by 10% to $188 primarily due to the impact of Genoptix and test mix shift. On a pro form a basis, cost per test decreased by 4.5% driven by increasing scale, automation and process improvement. In the Q4, cost per test increased by 14% year over year to $194 primarily due to the acquisition of Genoptix. On a pro form a basis, including Genoptix in the base year, cost per test was essentially flat on a year over year basis in the quarter. Pharma Services gross margin increased 540 basis points to 44.7% for the full year, but declined to 41.4% in the 4th quarter as we continued to build independent testing capacity for this business.
With a signed contract backlog of approximately $145,000,000 the pharma services business has reached a scale which necessitates its own testing infrastructure. We believe that having pharma testing decoupled from clinical testing will enhance efficiency in both divisions over time. We continue to expect that pharma services gross margin will expand for levels at or above clinical division margins over time. General and administrative expenses increased 29% or $7,500,000 year over year to $33,000,000 primarily due to the addition of Genoptix. G and A expense was flat sequentially.
G and A expense as a percent of revenue declined 2 50 basis points year over year, primarily due to the impacts of leverage and Genoptix cost synergies. Sales and marketing costs increased 53% year over year to $12,000,000 driven by the acquisition of Genoptix and the expanded size of our sales teams on both the clinical and pharma sides of the business. In the 4th quarter, funding for research and development increased fourfold as we continue to internally develop new testing solutions for our customers, including our next generation sequencing assays and single site PMA submission with the FDA. We have grown our team of scientists engaged in R and D and now have approximately 22 people dedicated to research and development. 4th quarter adjusted EBITDA increased 5% year over year to $13,600,000 which was in line with the midpoint of our guidance range.
While the quarter 4 adjusted EBITDA contribution was lower than normal due to activity surrounding the Genoptix integration and heavy investments in growth related activities. The incremental adjusted EBITDA contribution for the full year was 24%, close to our long term guidance of 25% to 35% EBITDA contribution on revenue growth. We exited quarter 4 with $173,000,000 in cash and $105,000,000 in debt. We have approximately $131,000,000 of availability on our credit facilities. You will note that after year end, we acquired the oncology division assets of human longevity for approximately $37,000,000 DSO increased 3 days year over year and one day sequentially to 81 days due to timing of payments.
Cash flow from operations was $23,000,000 for the year. We also issued full year 2020 revenue and earnings guidance. We expect revenue to be in the range of $464,000,000 to $474,000,000 which equates to 13% to 16% top line growth and adjusted EBITDA to be in the range of $60,000,000 to $65,000,000 Our EBITDA guidance reflects approximately $7,000,000 of incremental growth investments related to informatics and dilution related to the HLI acquisition. I will now turn the call over to Doug to provide commentary on our key growth initiatives.
Thank you, Catherine. Catherine provided full year guidance and we feel great about 2020. However, before addressing some of the key drivers and dynamics that have us feeling so optimistic about the full year growth, I want to set expectations for the Q1. Normally, we would expect to start the year strong and to gradually improve from there. Unfortunately, that is not the case for 2020.
Our forecast for profitability in the Q1 is significantly below what we would normally expect. There are several reasons for this. Most significantly, given the tremendous growth in Pharma Services backlog and our record quarter 4 revenue, we have built a global cost structure to support a high level of activity. Unfortunately, the timing of revenue conversion for pharma services projects in the Q1 looks to be down by approximately $4,000,000 sequentially. We had a number of projects end in December and a number of other large projects are not starting up until late March April.
Despite this timing dynamic, I can assure you that our team and our business is very healthy and our $145,000,000 in backlog of signed contracts gives us high confidence that pharma services revenue will continue to grow at rates exceeding 20% in subsequent quarters and for the year. 1st quarter adjusted EBITDA will also be impacted by dilution from the oncology division assets of Human Longevity's acquisition, which we just recently acquired and is not yet at a breakeven point. We expect adjusted EBITDA to also be lower as a result of our investment in informatics. We are executing our strategy and now have a team of 27 people working on informatics related initiatives. We expect these initiatives to strengthen our competitive position in both the clinical and pharma services division and provide an incremental stream and source of revenue with some of that beginning later this year.
We are being deliberate about our strategy and execution and are committed to this initiative. Even with confidence in our adjusted EBITDA guidance of $60,000,000 to $65,000,000 for the full year, our current expectation for Q1 adjusted EBITDA is approximately $8,000,000 Looking ahead to 2020 as a whole, I must say that we are extremely excited about our opportunities. That excitement is evident here in San Antonio, where we are holding our annual national sales meeting. I wish I could properly convey to our investors and customers why each of the nearly 150 attendees here are so excited, committed and driven. It's partly because they know they are saving lives and it's partly because they believe that we have an extraordinary competitive position and ability to lead and grow in this revolutionary time in oncology care.
We believe that we have the building blocks in place to be the leading global oncology diagnostics company. Our clinical division has an excellent market position and product portfolio. With the acquisition of Genoptix, we greatly expanded our distribution channel and gained an excellent market position with community oncology practices. We fortified our market position as the leading oncology lab for hospitals and pathologists by adding large national health system accounts, group purchasing contracts and managed care contracts. We are now contracted with every national payer and with most significant regional plans.
Technologically, we significantly enhanced our next generation sequencing capabilities and are rapidly emerging as one of the largest providers of oncology focused molecular testing in the country. In fact, during the Q4, we performed over 70,000 molecular and next generation sequencing tests in our clinical division, representing about 25% of our total volume of testing. This test category grew at a rate of approximately 50% compared with the prior year and we expect its growth rate to remain very strong. We plan to continue leveraging our market position with the introduction of new tests and services to help our customers deliver better care for cancer patients. Next generation sequencing is an area of particular development focus for us and we expect to introduce several products in 2020.
We're working hard on a suite of liquid biopsy offerings for cases where tissue samples are not possible to obtain and expect to complete our validation and introduce a pan cancer liquid biopsy test early in the second half. We are working to expand our offering of RNA based sequencing assays for both solid tumor and hematologic malignancies. We're also developing a rapid next generation sequencing panel designed for acute myeloid leukemia, which often requires prompt treatment. In addition, we're working on assays for identifying minimal residual disease, particularly for hematologic neoplasms. Because of our reach into thousands of hospitals and oncology practices, we are able to facilitate the adoption of these advanced oncology diagnostic tools beyond the academic environment into the community setting so that cancer patients can have access to the leading oncology care in their own communities.
Importantly, our team of over 120 MDs and PhDs along with the highly trained oncology focused sales team provide continuous education to our clients to ensure that they remain abreast of developments in oncology. In pharma services, we significantly strengthened our competitive position over the past year as well. Our pharma services division supports pharmaceutical clients on a global basis across the drug development continuum from research and development through clinical trials testing to commercialization of companion diagnostic tests. We currently provide service for more than 150 different clients around the world. We plan to grow our global pharma services business by expanding our market presence in both Europe and Asia and by expanding our test offering, particularly with leading edge next generation sequencing tools and unique capabilities for developing and commercializing companion diagnostic tests.
We made an important strategic move to build our pharma services product capabilities in January through the acquisition of the oncology division assets of human longevity. The team in La Jolla performs next generation sequencing services for pharmaceutical customers including germline, whole exome and whole genome sequencing. We now have an even more experienced specialized molecular workforce with strong next generation sequencing expertise, particularly in serving pharmaceutical companies. This business generated approximately $10,000,000 of revenue in 2019 and ended the year with a backlog of approximately $15,000,000 in signed contracts. Companion Diagnostics is an important area of growth as precision medicine and immunotherapies increasingly rely on these tests to predict their effectiveness in patients.
Included in our backlog of signed contracts are 30 different companion diagnostic assays for a variety of pharma and biotech companies. We are increasingly in discussions with pharma sponsors to help with companion diagnostic projects. We also have agreements with several large pharmaceutical companies to provide day 1 commercial launch services with advanced analytical support for companion diagnostic testing associated with drugs in the late stage pipeline. Few labs have our same ability to take an oncology companion test across the continuum from development through clinical trials and into the market. During 2019, we also laid the foundation for a new data and informatics business that will leverage our unique market position and oncology expertise to help our stakeholders solve real world problems such as identifying patients for clinical trials or implementing clinical decision support tools for physicians, healthcare systems, payers, pharma companies and patients.
While we are in the very early innings in terms of product development, we already have significant engagement from various stakeholders, including global pharmaceutical firms, large national health systems and major managed care payers. In 2020, we plan to continue to invest in our informatics division. We expect this division to be an incremental source of revenue in the long term, while strengthening our competitive position in both the clinical and pharma services divisions. In summary, 2019 was an exceptional year for NeoGenomics and we are extremely excited about our opportunities in 2020 and beyond. Oncology Diagnostics is an exciting place to be.
Advances in science and technology are driving a proliferation of oncology therapies and associated diagnostic tests. These diagnostic tools and therapies are increasing survival and enhancing quality of life for cancer patients. Our leading position in the market is proving to offer significant sustainable competitive advantages today and we are working hard to make our competitive position even stronger in the future as we pursue our vision to become the world's leading oncology diagnostics company. I'll now hand the call over to Bill Bonello to lead us through a Q and A session.
At this point, we'd like to open the call for questions. Incidentally, if you're listening to this conference call via webcast only and would like to submit a question, please feel free to e mail us at bill. Bonelloneogenomics.com during the Q and A session, and we'll address your questions at the end of the if the subject matter hasn't already been addressed by our call in listeners. As mentioned at the beginning of this call, we would like to ask each person to limit their questions to 2, so that we may hear from everyone and still keep within the hour allotted for this call. Jess, you may now open the call for questions.
Certainly.
We'll move first to Puneet Souda at SVB Leerink.
Hi, Doug. Thanks. Catherine, congrats on the new role. Great to have you on board here and great to have everyone, the entire team on the call here. So my first question, Doug, is on the guide.
I mean, it's almost 15% organic growth at the midpoint. I was hoping if you could parse out in terms of the contributions from NGS, that's a strong grower. Do you expect that to accelerate here and contributions from pharma? HLI, correct me if I'm wrong, but that's expected to contribute about $5,000,000 into this guide. And are you expecting multi gene panels and informatics effort to contribute here as well, if you could parse those out?
Thank you.
Well, thank you, Puneet. Thanks for the question and the comments. We do expect strong growth to continue in our business. This investments that we've made recently in informatics and pharma in the acquisition of the oncology division assets of human longevity should continue to fuel that organic growth that we've seen recently. Clearly, the organic growth is being driven partly by next generation sequencing and molecular testing.
We mentioned that those growth rates have been approximate dating 50%. And we have really restructured in some respects our NGS panels, and we think they are very, very high quality panels. We continue to make improvements in them in terms of number of genes and in our reporting capabilities and the marketplace is reacting very favorably to that. So our next generation sequencing panels in the clinical business should continue to fuel growth. In pharma, I mentioned in the script that we expect the revenue for the remainder of this year after quarter 1 to exceed 20%, which is our long term guidance there.
We've got very strong capabilities. Certainly, the acquisition of the assets of Human Longevity will continue to fuel that. Human Longevity's revenue for last year 2019 was about $10,000,000 and we would expect that to grow at least at the same rates that the pharma business is growing. In terms of multi gene panels, you know that we have a full portfolio of NGS and multi gene panels using our multi modality capabilities. And these multi gene and multi modality panels are growing very, very nicely.
A lot of our customers like targeted panels. There are also some customers are ordering the large panels. Some customers are also ordering just single gene molecular tests and we offer the full spectrum of those product opportunities. And lastly, you asked about informatics. I can tell you, we are really excited about our informatics strategy.
We are getting a lot of inquiries from pharma companies, from payers and others to help them solve problems that they have running their business. And in pharma's case, identifying patients for clinical trials or matching patients with therapies. And we're very excited about our capability, our expanding capability here. And we should expect to see revenue in the second half of twenty twenty and certainly beyond that.
Okay, that's great. My second follow-up is largely on NGS. Number 1, I was expecting a sequential improvement in ASP given the NGS continues to be an important driver for you in terms of growth and the contribution. So if you could elaborate in terms of ASP lift, when can we start to see that given NGS becoming larger? And I'm assuming NGS tests are being priced slightly higher than the current portfolio.
Also on NGS front, could you remind us again in terms of what's been the feedback from FDA and when can we expect the approval for the multi gene? And on the liquid efforts, if I could squeeze that into on liquid when second half launch as you pointed out, but should we expect it to go through the same regulatory pathway that you are taking the current multi gene panel? Thank you.
Okay, good. Puneet, thank you for those questions. In terms of next generation sequencing's impact on our average unit price, it is impacting our average unit price slightly and it will continue to do so. Our NGS panel tests are generally are significantly greater than the average of our price per test. Reimbursement is, I think, improving somewhat in next generation sequencing, although it's still difficult to get paid by some payers, but I see that environment improving somewhat.
So we would expect that there would be some favorable impact going forward in our AUP as a result of the increasing share of our test volume mix, held by next generation sequencing. We also have other reimbursement initiatives by the way that we expect will have a favorable impact on average unit price over time. In terms of FDA approval, we are continuing to work very hard to achieve FDA approval of a large panel of next generation sequencing assay that we've brought before the FDA. We have very good dialogues with the FDA. We've had some good recent dialogues with the FDA.
I must say we're learning as a result of this process and we would hope to make substantial progress by the end of the year and it's difficult to give real firm guidance with confidence as to when we would be through the FDA process because there are a number of learnings that we're having for sure. So the timing is a bit difficult to predict, but we are making very good progress. And I would hope that we would be through the process by the end of 2020. You also asked about liquid biopsy. We are in the process of developing a number and series of liquid biopsy product offerings.
One is a pan cancer liquid biopsy test, which we are in the process of validating right now. And we would expect that around summertime, we would be able to introduce that product commercially. We also have liquid biopsy offerings that we're working with partners on, which are in the single gene category and these are being sponsored partly with pharmaceutical companies. In addition to all that, we're working on other liquid biopsy opportunities for both our pharma business and potentially for our clinical business. So this is a very important area of growth for us and we will add liquid biopsy products to our comprehensive menu in 2020 beyond.
We'll
go next to Brian Weinstein at William Blair.
Hey, guys. Thanks for taking the questions. Maybe to dig in a little bit more on the guidance. Can you talk about the pricing dynamic versus volume growth in 2020? Also, are you within that, are you baking in share gains?
Or are we really thinking about industry growth for testing volume? And then I'll ask the second question here in a second. Thanks.
Okay. Thank you, Brian. In terms of volume gains in the clinical business, yes, we would expect to see continued market share gains. As we've talked about and I think you know, we have very strong competitive position. We're one of the few companies out there in our space that has a very comprehensive menu, which we keep up to date.
And we have a very cutting edge comprehensive menu serving cancer centers, pathologists, oncologists, academic centers and we continue to see market share gains as we have for some time. In terms of pricing, the pricing environment, even though we've had 6 straight quarters of increasing average unit price, is relatively stable. Now there are some dynamics there. One dynamic is that when we gain large group purchasing organization or large hospital contracts, national contracts, in some cases, there will be pricing concessions that we'll make. But as I said, we do have a little bit favorability in our test mix, which is improving our average unit price.
And the general market for next generation sequencing pricing is improving somewhat. So I think our guidance for average unit price is about down maybe 1% or so. We've guided historically to 2% to 3% annual decrease in AUP. And I think that would be a relatively reasonable expectation for you to have.
Great. And then for my second question, as it relates to the backlog and the conversion of that backlog and things getting pushed out a bit, can you give us a little bit more detail on your confidence that that's really what is going on here and that it's
not just broader slowdown in some
of the projects that you guys are working with your partners on or that some of these projects are maybe more unlikely to play out. So just whatever else you can give us on that because that was a bit of a surprise. Thanks.
Yes. We understand. We're just finishing our best year ever and we've got some terrific growth in pharma both in our backlog of signed contracts and we continue to add new signed contracts at a very robust pace. And I can assure you, we've got a sales team in pharma, which is terrific and they're very excited. So we don't see a slowdown in pharma over the long term at all.
In fact, what we're seeing is long term growth, which is meeting or exceeding our expectations. What we have in quarter 1 is a bit of an unusual dynamic where we did have projects that stopped or ended in December and we have a lot of projects which are starting in March April. It's an unusual dynamic. Now we also have some seasonality here. So January February March typically in pharma are seasonally a little bit weaker than the rest of the year.
We've seen that in the last couple of years and now pharma is a bigger piece of NeoGenomics and so that's impacting things a bit. But we have very, very strong confidence in our pharma business. We love the business. It is a unique property. It's one of the few businesses out there that can meet needs of the pharma customers on a worldwide basis with a comprehensive menu of products and we feel very good about it.
Great. I'll take my few questions. Thanks.
We'll go next to Joe Munda at First Analysis.
Good morning. Thanks for taking the questions. Can you hear me okay?
Yes, we can, Joe. Thanks.
So real quick, I just wanted to touch on the Q4 gross margin. Catherine said to give us some details on the year over year decline there. Commentary was talking about the integration of Genoptix as well as growth. So really a 2 part question. How much of the decline was due to the integration versus investments for future growth?
And then 2, I guess, as we look out, how much do we have left as far? If you could walk us through what's left in the Genoptix integration as well as the opportunity to maybe drive down costs in the second half? Thank you.
Sure, Joe. Let me take some of that and maybe Catherine will weigh in if necessary. First of all, I would say that the integration of Genoptix is going very well. We are now, I think, about 13 or 14 months into the integration process and we are about done. We have about 2 months left of integration where we are going to migrate the remaining Genoptix customers onto a single laboratory information and billing system.
And that will that activity will culminate in about 2 months' time and will set us up for a lot of progress both on the cost front and on other fronts going forward because we have a lot of folks who are involved in migrating the customers and still in preparing our IT systems and other processes to have a unified laboratory information and billing system. So that process did impact our gross margins in quarter 4 because we have somewhat redundant costs in place and a lot of people focused on finishing the integration activity. We but we feel very good about it. And we think that in the second half of twenty twenty, we are going to see some acceleration in our cost per test, our normal cost per test reduction activities. In terms of investments in growth impacting gross margin, I would point to pharma services where we have invested a lot in global expansion.
We've also invested a lot in separating and creating a separate laboratory infrastructure for Pharma Services because the pharma services business is getting to be a large part of NeoGenomics. And customer requirements in pharma are different than in the clinical business. And that is necessitating us to separate in the laboratory pharma business and activity from clinical business and activity. So in that sense, we've got a fair amount of cost that we've added for Singapore, for Geneva, for our laboratory systems and processes in the U. S.
And we feel great about it because there's a lot of growth. There's 140 $5,000,000 of signed contracts and backlog, which we're just ready and waiting to execute. So our gross margin was pressured to some extent in quarter 4, but we would expect our gross margins to rebound in the second half of twenty twenty.
Okay.
And then Doug, just one follow-up to that, the relationship with PPD, can you comment on that as well as incremental revenue as a result of that relationship? Thanks.
Yes, Joe, I could comment, but George Cardoza would do a better job. So let me pass the mic to George. We're very pleased with
the relationship with PPD. They're a very valued partner. We're literally right across the hall from them in Singapore and they were invaluable in setting that office up. We have gotten quite a few, actually several $1,000,000 in contract wins for them. For competitive reasons, we don't give out the specific dollar amount, but I would say we're pleased with that partnership.
We're a year and a half in and I think we're working really well with them and I think both sides realize that there's still a lot more upside in that relationship that's to be had. So I would say it's on track and I think the future looks very bright for our partnership.
Okay.
Thank
you. We'll go next to Bruce Jackson at The Benchmark Company. Hi.
Thank you for taking my question. The informatics strategy sounds very exciting. I wanted to know if we could get maybe some more details on the clinical decision support tools.
Sure, Bruce. I mean, I think the concept here is that with the rapid evolution in testing technologies and just what's going on in terms of cancer therapeutics, it's getting increasingly difficult for providers to know which are the most appropriate tests to be ordering. And so the at the most basic level, the concept for clinical decision support is, if we could integrate tools, for instance, into our online ordering or through working with payers or working directly with health systems that would better direct physicians to appropriate tests based on the situation with the patient that we could help improve ensuring that patients are getting the right testing. I mean a simple example that we use as an illustration often is non small cell lung cancer patient that maybe gets a PD L1 test, but doesn't get the corresponding molecular test that should be ordered, if we can design tools that could sort of automatically inform those providers about guidelines and alert them when patients haven't gotten testing that's sort of consistent with guidelines, etcetera, we think that could make a big difference in improving patient care.
Okay. Thank you. And then a fast question on the pharmaceutical side of the business. Is the timing of the project starts, does that have anything to do with the coronavirus? You've got a global footprint.
And, just wondering if there's any impact to that particular business?
We're an oncology laboratory. So yes, really that doesn't the coronavirus or COVID-nineteen doesn't lapse over to our business. So I do think right now we have a couple of projects that we are managing through our partner. We do have a partner in China that we've been working with. Those projects have slowed down, so there could be a minor, minor drag on this.
But in terms of our overall pharma revenue, it's not a material amount of our overall revenue.
And with no other questions holding, I'll turn the conference back to Mr. Van Oort for any additional or closing comments.
Okay. Thank you, Jess. As we end the call, I'd like to recognize the approximately 1678 NeoGenomics team members around the world for their dedication and commitment to building a world class oncology diagnostics company. On behalf of our NeoGenomics team, I want to thank you for your time joining us this morning. For those of you listening that are investors or are considering an investment in NeoGenomics, we thank you for your interest in our company.
Goodbye.
Ladies and gentlemen, that will conclude today's call. We thank you for your participation. You may disconnect at this time and have a great day.